Latest @ CSI

Autocrine Human Growth Hormone Stimulates the Tumor Initiating Capacity and Metastasis of Estrogen Receptor-Negative Mammary Carcinoma Cells. (Cancer Lett, Jun 2015)

Chen YJ1, Zhang X2, Wu ZS3, Wang JJ1, Lau AY1, Zhu T4, Lobie PE5.

1 Department of Pharmacology, National University of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
2 The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027.
3 Department of Pathology, Anhui Medical University, Hefei, Anhui, China.
4 The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027; Hefei National Laboratory for Physical Sciences at Microscale, Hefei, Anhui 230027, China.
5 Department of Pharmacology, National University of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.

Abstract:
The oncogenic effects of autocrine human growth hormone (hGH) have been intensively investigated in estrogen receptor-positive mammary carcinoma (ER + MC) cells. We demonstrated herein that autocrine hGH promoted cancer stem cell (CSC)-like properties of estrogen receptor-negative mammary carcinoma (ER-MC) cells in vitro. In xenograft studies, autocrine hGH increased the tumor initiating capacity of ER-MC cells. We also observed that autocrine hGH promoted migration and invasion of ER-MC cells in vitro, and metastasis in vivo. Thus, inhibition of hGH is a potential therapeutic strategy to prevent tumor initiation and metastasis of ER-MC.